Asperuloside as a Novel NRF2 Activator to Ameliorate Endothelial Dysfunction in High Fat Diet-Induced Obese Mice
<b><i>Aims:</i></b> Current treatments are inadequate in alleviating obesity-associated vascular diseases. The development of effective therapies to ameliorate endothelial dysfunction and attenuate oxidative stress is of utmost importance. Asperuloside (ASP), a bioactive compound extracted from <i>Eucommia species</i>, exhibits antiobesity properties. However, the effects of ASP on vasculopathy have not been investigated. Therefore, the effects of ASP on vascular dysfunction and related mechanisms were elucidated. <b><i>Results:</i></b> ASP significantly reversed the impaired endothelium-dependent relaxations (EDRs) in obese mice and interleukin (IL)-1β-treated aortas. ASP suppressed endothelial activation in obese mice aortas and IL-1β-treated endothelial cells. ASP attenuated oxidative stress, scavenged mitochondrial reactive oxygen species (ROS), and upregulated heme oxygenase-1 (HO-1) expression in endothelium, independent of its anti-inflammatory properties. HO-1 knockdown diminished the protective effects of ASP against impaired EDRs, ROS overproduction, and endothelial activation. Endothelial cell-specific nuclear factor erythroid 2-related factor 2 (Nrf2) knockdown eliminated the ASP-mediated vascular protective effects and endothelial HO-1 upregulation, emphasizing that ASP improves endothelial function by activating Nrf2/HO-1 signaling. ASP facilitated Nrf2 nuclear translocation and the direct binding of Nrf2 to antioxidant response element, thereby enhancing HO-1 transcription and scavenging ROS. The cellular thermal shift assay results provide the first experimental characterization of the direct binding of ASP to Nrf2. <b><i>Conclusions:</i></b> These findings demonstrate that ASP ameliorates obesity-associated endothelial dysfunction by activating Nrf2/HO-1 signaling and thereby maintaining redox hemostasis, suggesting its potential as a novel Nrf2-targeted therapeutic agent and dietary supplement for vasculopathy. <i>Antioxid. Redox Signal.</i> 42, 77-96.
Authors
- Yu Huang (ORCID: https://orcid.org/0000-0003-4535-4331)
- Gary Tse (ORCID: https://orcid.org/0000-0001-5510-1253)
- Chui Yiu Bamboo Chook (ORCID: https://orcid.org/0000-0002-1366-6990)
- Lei He (ORCID: https://orcid.org/0000-0002-8615-5673)
- Zhen‐Yu Chen (ORCID: https://orcid.org/0000-0001-5615-1682)
- Huixian Li (ORCID: https://orcid.org/0000-0001-5722-8602)
- Chufeng He (ORCID: https://orcid.org/0000-0003-0327-3779)
- Fung Ping Leung
- Ruiwen Zhu
- Wing Tak Wong (ORCID: https://orcid.org/0000-0002-4514-3780)
Institutions
- City University of Hong Kong (HK)
- Chinese University of Hong Kong (HK)
- Chinese University of Hong Kong, Shenzhen (CN)
- Second Hospital of Tianjin Medical University (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Antioxidants and Redox Signaling
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1089/ars.2024.0593
- Citations
- 7
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 2.06